

Aon Health and Benefits and Reformulary Group Announce Strategic Alliance

Relationship matches Aon's health and benefits consulting expertise with Reformulary Group's specialist drug expertise and proven drug plan solution

TORONTO (Tuesday, 3 October 2017) — Reformulary Group, a leader in drug plan management with its evidence-based Reformulary® and drug and data analytics capabilities, and Aon Canada, a leading global professional services firm, today announced a strategic alliance whereby Reformulary will be Aon's partner in formulary design, and both parties will integrate its analytics into a powerful solution.

"Aon has a leading position in the health and benefits consulting space, as well as a significant client base reaching out for drug plan sustainability," said Helen Stevenson, Founder and CEO of Reformulary Group Inc. "We hope to use our combined expertise to bring solutions to Aon's clients and help them to achieve better health and financial outcomes." Reformulary Group brings specialist advice in the drug space, both related to employer-sponsored plans and provincially-funded drug plans.

"By both firms working collaboratively, we are able to serve our clients in an evolving and complicated drug environment," said Anthony Perlman, Senior Vice President and National Practice Leader, Aon Health and Benefits. "Clients spend a significant amount of money, from both an employer and employee perspective, and this partnership is another example of our continued focus on driving value for our clients. The output from this partnership will better assist plan sponsors in managing this aspect of the benefits programs."

The two companies plan to collaborate and leverage Aon and Reformulary's respective data analytics capabilities to provide even more powerful, combined offerings. Earlier this year, Reformulary launched its Drug Early Warning (DEW) System™ to monitor the pipeline of new high-cost prescription drugs entering the Canadian marketplace and forecast the expected impact of these drugs on drug benefit plans.

The non-exclusive strategic alliance allows each party to continue to collaborate with other firms and partners.

About Aon

Aon plc (NYSE:AON) is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatility and improve performance.

About Reformulary Group

Reformulary Group is a specialized formulary management and health analytics company, founded in Toronto in 2011. The company's most notable innovation is its proprietary formulary – the Reformulary® – which it sells on a subscription basis to Canadian employers. The Reformulary is curated based on the trusted advice of an independent panel of doctors and pharmacists, which reviews massive amounts of research and evidence about drugs. Plans powered by Reformulary achieve significant savings and encourage members to make informed choices about the drugs they take. DrugFinder™ is an app to search the Reformulary, and help people make smart drug choices and take control of their health.

www.reformulary.com

Media contacts:

For Reformulary Group

Lyndsay Wallis

MAVERICK PR

t +1.416.640.5525 x240 | m +1.226.979.6941

lyndsaw@wearemaverick.com

News Release



For Aon Hewitt Canada
Sonya Malcolm
t +1.416.868.5895
sonya.malcolm@aon.ca